Kornimate/medical-research-clean huggingface dataset:
evaluation of microcirculation in colon wall and bowel anastomosis by laser induced fluorescence video angiography

Conditions: Colon Cancer; Benign Colon Diseases

Summary: the aim of the study is to describe utility of dynamic fluorescence videoangiography of indocyanine green (icg) in gastrointestinal surgery, for evaluation of microcirculation in colon wall and anastomosis before and after surgical resection; and if this technique can guide the surgeon to peroperative decision making considering recreate a new anastomosis or stoma for preventing anastomotic failure or stomia necrosis.

in our study the investigators prospectively include patients with colon cancer requiring elective surgical operation. all types of colon resection were carried out according to standard procedures. guidelines for preoperative examination according to ngicg (norwegian gastro-intestinal cancer group) to grade the disease, select the most suitable patients and plan further treatment. microcirculation of colon wall was assessed by dynamic laser-induced-fluorescence-videoangiography (ic-view, pulsion medical systems ag, munich, germany) of indocyanine green (icg). icg is a water-soluble tricarbocyanine dye that binds strongly to plasma proteins after intravenous injection and is exclusively distributed in intravascular space. additionally this system houses a laser (energy pi = 0.16 w, wavelength = 780 nm) that causes excitation/illumination of the fluorescence light from intravascular plasma bound icg. this light has a spectral range near-infrared energy (nir) with a maximum at 805 nm and emits fluorescence at 835 nm. it passes through infrared filter on a digital video camera and results in recording of real time fluorescent image from perfusion of plasma bound icg within small plexus of blood vessels in the bowel wall. besides that it also demonstrates perfusion from surrounding structures such as appendix epiploic and pericolic fat. the maximum penetration of the laser into tissue is 3-5 mm and general normal thickness of colon wall is 3-5 mm. this method makes it a presentable tracer for tissue perfusion of anterior bowel wall.

Eligibility criteria:
inclusion criteria: * patients with colon cancer requiring elective surgical operation. exclusion criteria: * pregnancy * children or patients below the age of 18 years * advanced renal or hepatic failure * previous allergic reactions to icg and iodide * chronic anemia * active haematologic disease * women of fertile age needed a negative pregnancy test to be included * patients with previous colectomy or anorectal surgery were also excluded due to anatomical insult on mesenterial circulation

Keywords: microcirculation colon anastomosis icg gastro surgery benign colon diseases requiring resection
effects of combined therapy with statin plus fenofibrate on coronary atherosclerotic plaque compared with statin alone

Conditions: Coronary Artery Disease

Summary: the purpose of this study is to determine effects of combination therapy with rosuvastatin and fenofibrate on atheromatous plaques and its tissue characteristics of de novo coronary lesions with intermediate stenosis in patient with coronary artery disease, compared with rosuvastatin alone therapy.

cardiovascular disease remains the leading cause of morbidity and mortality worldwide. in the past few decades, optimal pharmacological therapies with statins targeting ldl-cholesterol substantially reduce the risks of cardiovascular disease. however, the residual cardiovascular risk is still high, requiring need for additional preventive therapies to achieve even greater risk reduction. recent meta-analysis demonstrated fibrates can reduce the risk of coronary events and might have a role in patients with high cardiovascular risks or combined dyslipidemia. likewise, fenofibrate had a possible benefit for patients with high triglyceride level and low hdl-cholesterol level in the post-hoc analysis of accord or field trials. thus, investigators tried to determine effects of combination therapy with rosuvastatin and fenofibrate on atheromatous plaques and its tissue characteristics of de novo coronary lesions with intermediate stenosis in patient with coronary artery disease, compared with rosuvastatin alone therapy.

Eligibility criteria:
inclusion criteria: * patients with coronary artery disease who were 20 years of age or older and needed coronary angiography * intermediate coronary artery stenosis (diameter stenosis ≥30% to ≤60% by visual estimation, diameter ≥2.0 mm to ≤4.0 mm, de novo lesion in native coronary artery) in which virtual histology-intravascular ultrasound (vh-ivus) could be feasible * combined dyslipidemia * stain-naive patients - ldl-cholesterol ≥70 mg/dl and non-hdl-cholesterol ≥130 mg/dl * patients taking statin within 2 weeks - ldl-cholesterol \< 100 mg/dl and non-hdl-cholesterol ≥100 mg/dl * patients who gave written informed consent exclusion criteria: * diabetic patients * cardiogenic shock * heart failure with symptoms of new york heart association class iii/iv or left ventricular ejection fraction \<35% * renal dysfunction (creatinine level ≥1.7 mg/dl or dependence of dialysis * hepatic dysfunction (transaminase level \> 3 times of normal within limit) * pregnancy or breast-feeding women * familial hypercholesterolemia * hypertriglyceridemia (triglyceride level \>500 mg/dl)

Keywords: atherosclerotic plaque virtual histology intravascular ultrasound plaque composition rosuvastatin fenofibrate coronary artery disease
surgicel® (fibrillar) in non-variceal ugi bleeding

Conditions: Non-variceal Upper Gastrointestinal Bleeding

Summary: the aim of this study is to assess of effect of surgicel® (fibrillar) for preventing delayed bleeding after endoscopic hemostasis in non-variceal upper gastrointestinal bleeding


Eligibility criteria:
inclusion criteria: * patients with non variceal upper gastrointestinal bleeding proven by esophagogastroduodenoscopy * patients with active bleeding (forrest classification ia or ib or iia) exclusion criteria: * patients with upper gastrointestinal tract malignancy * patients with acute severe illness * coagulopathy: liver cirrhosis, thrombocytopenia * pregnant women
effects of branched-chain amino acids on muscle ammonia metabolism in patients with cirrhosis and healthy subjects

Conditions: Liver Diseases; Hepatic Encephalopathy; Hepatic Insufficiency

Summary: the purpose of this study is to determine whether branched chain amino acids enhances the uptake of ammonia in muscle tissue.

branched-chain amino acids (bcaa; leucine, valine, isoleucine) are used to prevent hepatic encephalopathy in cirrhotic patients. the main effect of bcaas is believed to take place in muscles where bcaas provide carbon-skeletons for the tca-cycle. this enhances the conversion of alfa-ketoglutarate to ammonia via glutamine. we intend to study the effect of oral administered bcaa on the metabolism of ammonia and amino acids across the leg-muscles by means of catheters inserted into the femoral artery (a) and vein (v). muscle blood flow (f; l/min) will be determined by constant infusion of indocyanine green and indicator dilution principle. arterial blood flow and a and v concentrations of ammonia and amino acids will be measured before an oral load of bcaa (0.45 g bcaa/kg body weight) and after 1 and 3 hours. the metabolism of ammonia will also be estimated by means of 13n-nh3 pet scans. hypothesis: bcaa increases the uptake of ammonia in muscle tissue and lowers arterial ammonia.

Eligibility criteria:
inclusion criteria: * 18 patients with liver cirrhosis * 6 healthy subjects age and sex matched exclusion criteria: * non-treated diabetes * pregnancy/breast-feeding

Keywords: ammonia citric acid cycle branched chain amino acids
umbilical cord care for the prevention of colonization

Conditions: Line Insertion Site; Central Line-associated Bloodstream Infection (CLABSI)

Summary: umbilical catheters are necessary for many infants admitted to the newborn intensive care unit (nicu)and utilized when indicated for up to 7 to 14 days. bacterial colonization can occur at the umbilical stump and potentially lead to serious bloodstream infections (bsis). this study is a prospective, randomized controlled feasibility trial to evaluate three types of hygiene products on umbilical line stumps, on the effect of line colonization and subsequent infections. infants admitted to the nicu with an umbilical line(s) will be randomized into one of four study groups, three products against standard of care (no product). the three products that will be evaluated are currently being used in different capacities for skin care in the university of virginia (uva) nicu. the study hypothesizes that twice daily topical application of 1 or more antiseptic to the top of the umbilical stump will decrease colonization of the umbilical stump while umbilical lines are in place.

umbilical catheter associated infections are higher (4.4 vs. 3.4 clabsis per 1000 line days) than other central lines such as peripherally inserted central catheters (piccs) and surgically placed central venous lines (cvl) in the nicu. (www.cdc.gov - nshn 2010 report). routine care of the skin entry site (e.g. central line dressing care) is standard for other central lines, but there is no standard for care of the umbilical stump while umbilical lines are in place. in a pilot study to evaluate the relationship of umbilical stump colonization with gestational age, the number of days the catheter was in place, and the type of organisms, colonization was detected in 78% of patients. there was a direct correlation with colonization and line days as well as an inverse relationship with lower gestational age. this pilot data supported the need for the study of interventions to reduce umbilical stump colonization, which may help decrease blood stream infections (bsis) associated with umbilical lines in the nicu. the proposed study will evaluate feasibility of twice daily product application.

Eligibility criteria:
inclusion criteria: \*≤7 days of life \*umbilical line(s) in place (umbilical arterial catheter=uac and/or umbilical venous catheter=uvc) exclusion criteria: \*not meeting inclusion criteria

Keywords: prematurity central line care umbilical line colonization colonization newborn intensive care unit neonatal intensive care unit
comparative study between posterior lumbar interbody fusion(plif) and intertransverse process fusion in treatment of spodylolithesis

Conditions: Lumbar Spondylolisthesis

Summary: the first technique described for interbody fusion was the anterior lumbar interbody fusion (alif).(20) for this technique, the intervertebral disc is accessed through a retroperitoneal or transperitoneal approach. while the posterior approach was first described by russell hibbs in 1911, in the 1950's, cloward (7)popularized the posterior approach for a posterior lumbar interbody fusion (plif).

in this study we will try to identify the benefits and outcome of posterior lumbar interbody fusion and inter transverse process bone graft fusion.

Eligibility criteria:
inclusion criteria: * lumbar spondylolisthesis exclusion criteria: * infection of lumbar spine
beef burger versus a vegetarian burger

Conditions: Inflammation

Summary: the purpose of this graduate student research study is to compare the rise of serum lipids, glucose, and hs-crp levels after consumption of a beef burger versus a vegetarian burger in healthy adults between the ages of 21 and 55

visit 1 * sign an informed consent. * complete a brief questionnaire about demographics (age, gender, and race), eating habits, physical activity level, and medical history (known allergies, and history of dyslipidemia, diabetes mellitus, or arthritis) * will be directed to fast for 8 hours prior to visit 2. visit 2 * be randomized into either group 1 or group 2. one group will eat the beef burger first and the other group will eat the vegetarian burger first. * fill out a questionnaire on number of hours slept and current stress level. * take a finger prick test (tiny drop of blood) to determine baseline measurements for serum lipids, glucose, and hs-crp levels. * consume either a beef burger or vegetarian burger. * afterwards, remain in nichol hall, room a112, for 2 hours (may study, watch a movie, etc.). * may not consume anything except for water. * after 30 min, 60 min, 120 min, finger prick tests will be used to measure post-consumption serum lipids, glucose, and hs-crp levels. * will be asked to try and identify burger consumed and rate the taste of the burger. * will be directed to fast for 8 hours prior to visit 3. visit 3 * repeat the same procedure as visit 2. however, this time the burgers will be switched.

Eligibility criteria:
inclusion criteria: * healthy adults between 21 and 55 years of age * consume both beef and vegetarian products * no distaste for whole wheat buns, lettuce, soy, tomatoes, or vegan mayonnaise * willing to abstain from caffeine and exercise the morning of visits (2 days) exclusion criteria: * those allergic to the following food items: * gluten * lettuce * soy * tomatoes * vegan mayonnaise * have a known history of dyslipidemia, diabetes mellitus, or arthritis
study to evaluate efficacy and safety of pf-04965842 in subjects aged 12 years and older with moderate to severe atopic dermatitis

Conditions: Dermatitis, Atopic

Summary: b7451012 is a phase 3 study to evaluate pf-04965842 in patients aged 12 years and older with a minimum body weight of 40 kg who have moderate to severe atopic dermatitis. the efficacy and safety of two dosage strengths of pf-04965842, 100 mg and 200 mg taken orally once daily, will be evaluated relative to placebo over 12 weeks of study participation. eligible patients will have an option to enter a long-term extension study after completing 12 weeks of treatment.


Eligibility criteria:
inclusion criteria: * 12 years of age or older with a minimum body weight of 40 kg * diagnosis of atopic dermatitis (ad) for at least 1 year and current status of moderate to severe disease (\>= the following scores: bsa 10%, iga 3, easi 16, pruritus nrs 4) * recent history of inadequate response or inability to tolerate topical ad treatments or require systemic treatments for ad control exclusion criteria: * unwilling to discontinue current ad medications prior to the study or require treatment with prohibited medications during the study * prior treatment with jak inhibitors * other active nonad inflammatory skin diseases or conditions affecting skin * medical history including thrombocytopenia, coagulopathy or platelet dysfunction, q wave interval abnormalities, current or history of certain infections, cancer, lymphoproliferative disorders and other medical conditions at the discretion of the investigator * pregnant or breastfeeding women, or women of childbearing potential who are unwilling to use contraception

Keywords: atopic dermatitis atopic eczema eczema jak janus kinase
evaluating qol and postoperative complications using tetha technique in the treatment of tributary veins

Conditions: Varicose Veins; Quality of Life; Laser

Summary: endovenous laser thermoablation is a well-established alternative for the treatment of tributary veins. we believe that it is possible to improve the techniques described in the literature, aiming not only to allocate the laser fiber within the venous lumen, but mainly to transfix the vessel walls - a technique called tetha (transfixing endovenous thermal ablation).

endovenous laser thermoablation is an alternative for the treatment of tributary veins that is not yet one of the main alternatives in our specialty's consensus. in order to treat tributary veins applying laser, several punctures and the complete placement of introducer catheters are recommended in order to position the endolaser fiber in the lumen of the varicose vein before performing thermoablation of the saphenous veins. however, we believe that it is possible to perform an adequate treatment with a smaller number of punctures, aiming not only to place the laser fiber inside the venous lumen, but mainly to transfix the vessel walls - a technique called tetha (transfixing endovenous thermal ablation). our aim is to carry out a prospective cohort study to assess the aberdeen score in patients undergoing the tetha technique for the treatment of tributary veins.

Eligibility criteria:
inclusion criteria: patients with varicose veins \> 2mm associated with reflux of great or small saphenous veins with ceap c2 to c6 exclusion criteria: patients under 18 years acute or previous thrombophlebitis or deep vein thrombosis. pregnant patient. reject the informed consent form.
protocol for rct of posturing in phacovitrectomy for full thickness macular hole (ftmh)

Conditions: Full Thickness Macular Hole

Summary: the purpose of this study is to determine the effect of postoperative posturing on the outcome of macular hole surgery. current practice is divided; some individuals are advised to posture face-down for 10 days and others are advised that posturing is unnecessary. by evaluating the effect of posturing in a prospective randomised controlled trial the investigators hope to determine best practice, enabling surgeons and patients to make informed decisions regarding postoperative management.


Eligibility criteria:
inclusion criteria: 1. patients having surgery for idiopathic full thickness macular hole 2. able and willing to posture face-down for 10 days postoperatively 3. agree to participate in the trial and able to give informed consent exclusion criteria: 1. history of visual loss suggesting a duration of macular hole greater than 12 months 2. patients unable or unwilling to posture face-down for 10 days postoperatively 3. history of trauma that may have been causative 4. age less than 16 years (in practice idiopathic macular hole is extremely rare in patients under 30 years). 5. previous vitrectomy surgery 6. additional retinal breaks occurring during surgery that necessitate post-operative posturing to prevent retinal detachment.

Keywords: macular hole vitrectomy prone posturing
physical exercise for breast cancer survivors: face-to-face versus home-based

Conditions: Breast Cancer

Summary: the present investigation is a pilot feasibility study that aims to compare a physical exercise intervention in a face-to-face context (considered state of the art) with a physical exercise intervention in a distance context (online), both supervised, in women, of legal age, physically inactive, breast cancer survivors after primary treatment with curative intent. before and after the intervention these women will have a physical and functional assessment, as well as a pre-trial cardiopulmonary exercise test, to check if there are safety conditions to participate and also to self tailor the exercise prescription. the prescription follows the acsm´s exercise guidelines for cancer survivors and will comprise a 8 week combined exercise training, 3 times per week, in which two of them will be supervised and the third session of the week (cardio session) won´t. chat´s and weekly personal messages, as well as education, will be used to promote retention and exercise adherence.


Eligibility criteria:
inclusion criteria: * women * over legal age * with diagnosis of breast carcinoma between stages 0 and iiic * ecog 0 to 1 * undergoing primary treatment with curative intent (surgery associated or not, with chemotherapy and / or adjuvant radiotherapy) for at least one month * with follow-up on medical oncology consultation at chvng/e * with consent of the attending oncologist for the practice of physical exercise * non-compliance with current physical activity guidelines recommended by the acsm (moderate aerobic activity\> = 150 min / week or vigorous\> = 75 min / week and \> = 2 strength training sessions / week) * with cognitive capacity to understand the project proposal exclusion criteria: * severe anaemia seen in the last 3 months (hb \ 8 and \<= 10 g / dl) symptomatic (sustained tachycardia, exertional dyspnea, chest pain or syncope), * uncontrolled arterial hypertension (htn grade 3-4 (ctcae v.5)) (sad\> = 160mmhg and / or dad\> = 100mmhg) and / or potentially fatal consequences (malignant htn, transient or permanent neurological deficit or hypertensive crisis) * uncontrolled diabetes mellitus * known cardiac or respiratory pathology * any other contraindication given by the physiatrist and / or assistant surgeon
lipidomics and functional analyses of platelets in fabry disease

Conditions: Fabry Disease

Summary: this study aims to evaluate whether platelets are biochemically and functionally altered in fabry disease (fd) and therefore possibly implicated in fd manifestations such as cerebrovascular events. to test this hypothesis the investigators aim to compare platelet and plasma lipid profiles, as well as platelet function and coagulation parameters of fd patients and healthy controls.

fabry disease (fd) is a severe x-linked inborn error of the lysosomal glycosphingolipid metabolism. fd patients have significantly increased risks for cardiac and cerebrovascular events, which can also occur early and in absence of the typical fd symptoms. however, the pathophysiological mechanisms leading to vascular occlusion and ischemia in fd are largely unclear. prevention of recurrent cerebrovascular events is usually based on empirical anti-platelet therapy. prothrombotic states and partially activated platelets have been reported for fd patients. platelets contain glycosphingolipids, including globotriaosylceramide (gb3), and have lysosomal α-galactosidase activity. to investigate whether the lack of or the reduced α-galactosidase enzyme activity present in fabry disease affects platelet lipid metabolism the investigators plan to perform lc-ms-based lipidomics analyses of platelets and plasma in fd patients and healthy controls. to assess whether platelets are functionally altered in fd, the investigators aim to determine the activation status, activability, aggregability and other parameters along with plasma markers of coagulation using flow cytometry, aggregometry and immunoassays.

Eligibility criteria:
inclusion criteria: * healthy volunteers: without any known cardiovascular, cerebrovascular and renal diseases and without any known conditions affecting platelet function, blood coagulation and lipid metabolism. * patients: genetically confirmed fabry disease * adult persons (18-65 years old), both female and male * informed written consent exclusion criteria: * failure to meet inclusion criteria * pregnancy (as declared by the study participant, no pregnancy test will be performed)

Keywords: fabry disease platelets lipidomics sphingolipids α-galactosidase a globotriaosylceramide gb3 gl-3 cd77 alpha-galactosidase platelet activation lysosomal storage disease lysogb3 spingosine-1-phosphate platelet function cd62p p-selectin
determination of normal measures of optic nerve sheath diameter in children

Conditions: Optic Papilla Edema

Summary: the purpose of this study is to measurement of optic nerve sheath diameter in children without intracranial pressure increase and determine the average optic nerve sheath diameters for healthy children.

the purpose of this study is to measurement of optic nerve sheath diameter in children without intracranial pressure increase and determine the average optic nerve sheath diameters for healthy children. for that, between 4 and 18 years old children will be selected. after taking of measurements, following parameters will be taken into account and measurements will be classified with those parameters . 1. age 2. gender 3. length (cm) 4. weight (kg) 5. waist circumference (cm) 6. body mass index

Eligibility criteria:
inclusion criteria: • children without cerebral edema. exclusion criteria: • children with cerebral edema.

Keywords: optic nerve sheath diameter average optic nerve sheath diameter for healthy children